Fast actionable Strategic opportunity to position the tech as a faster alternative to conventional antibiotic susceptibility testing, enabling hospitals to cut time-to-result from days to under 24 hours and potentially reduce mortality costs associated with bloodstream infections.

Cost efficient Highlight the SMS array based Reveal system as a low-cost, labor-saving solution that can streamline lab workflows and lower per-test expenses, appealing to mid- to large-size hospital labs and regional reference centers seeking budget-friendly diagnostics.

Expansion synergy Leverage bioMérieux’s global manufacturing and European footprint to propose co-developed or co-branded manufacturing and distribution partnerships, accelerating scale and facilitating entry into European markets for rapid susceptibility testing.

Clinical impact Emphasize the potential to improve patient outcomes by enabling rapid, targeted antibiotic therapy in sepsis management, aligning with hospital acquisition priorities such as sepsis campaigns and value-based care incentives.

Collaborative growth Position opportunities with affiliated diagnostics platforms and service providers (e.g., Minaris and BIOFIRE ecosystem) to expand prevalence of rapid mycoplasma and resistance testing, offering integrated solutions and faster time-to-market for customers.